47 Rue Adrienne Bolland
Bringing better therapies to patients faster through stem cell technology
Ncardia has attracted a leadership team of international experts in the areas of commercialization, pharma services, finance, stem cell R&D and manufacturing.
Ncardia is a privately held Belgium-based company with subsidiaries in the Netherlands and the USA. The investor base of the company includes both public and private funds including Vesalius Biocapital, SFPI-FPIM, SambrInvest, InnovationQuarter, S.R.I.W, Sino-German beta Holding Co. Ltd and founders.
Ncardia was formed in August 2017 following an acquisition by Pluriomics. Pluriomics was founded in 2011 by Stefan Braam and Herman Spolders, together with the scientific founders Prof. Dr. Mummery and Prof. Dr. Passier.
Ncardia is a leader in contract research, development and manufacture of human induced pluripotent stem cell-based solutions. Our capabilities include disease modeling, assay development, large-scale iPSC manufacturing, and iPSC-based screening. Ncardia is a dedicated team of iPSC experts that uses our industry knowledge and experience to develop and deliver innovative stem cell-based solutions to drug discovery and cell therapy.